Skip to main content
Premium Trial:

Request an Annual Quote

Sophia Genetics Providing NHS, Turkish Lab Access to Bioinformatics Platform

NEW YORK (GenomeWeb) – Bioinformatics firm Sophia Genetics today announced deals with the UK's National Health Service and an unnamed Turkish laboratory to provide them access to the company's data-driven medicine platform.

The platform offers a secure software-as-a-service module for the analysis, validation, quality control, and presentation of genetic tests to clinicians, as well as storage and data sharing capabilities.

Lausanne, Switzerland-based Sophia said that it has developed algorithms based on machine learning and iterative Bayesian mathematics for an unbiased view of the data.

"As next-generation sequencing becomes more common, we are seeing more oncologists and clinicians demand the degree of accuracy and readability that Sophia Genetics offers, and we take pride in the fact that we provide them with unique reports they can act on immediately," Sophia CEO Jurgi Camblong said in a statement.

Last week, the company announced it obtained the CE-IVD mark for its next-generation sequencing bioinformatics pipeline for routine genetic testing. Earlier in the summer it said that it raised $13.75 million in a Series B financing round.